NO941310L - Sammensetning og fremgangsmåte for behandling av hepatitt C - Google Patents

Sammensetning og fremgangsmåte for behandling av hepatitt C

Info

Publication number
NO941310L
NO941310L NO941310A NO941310A NO941310L NO 941310 L NO941310 L NO 941310L NO 941310 A NO941310 A NO 941310A NO 941310 A NO941310 A NO 941310A NO 941310 L NO941310 L NO 941310L
Authority
NO
Norway
Prior art keywords
thymosin
hepatitis
treatment
composition
immune system
Prior art date
Application number
NO941310A
Other languages
English (en)
Norwegian (no)
Other versions
NO941310D0 (no
Inventor
Paul Chretian
Milton Mutchnick
Kenneth E Sherman
Original Assignee
Alpha 1 Biomedicals Inc
Milton Mutchnick
Kenneth E Sherman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha 1 Biomedicals Inc, Milton Mutchnick, Kenneth E Sherman filed Critical Alpha 1 Biomedicals Inc
Publication of NO941310D0 publication Critical patent/NO941310D0/no
Publication of NO941310L publication Critical patent/NO941310L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2292Thymosin; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
NO941310A 1991-09-13 1994-04-12 Sammensetning og fremgangsmåte for behandling av hepatitt C NO941310L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13
PCT/US1992/007556 WO1993005806A1 (en) 1991-09-13 1992-09-08 Composition and method of treating hepatitis c

Publications (2)

Publication Number Publication Date
NO941310D0 NO941310D0 (no) 1994-04-12
NO941310L true NO941310L (no) 1994-04-12

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941310A NO941310L (no) 1991-09-13 1994-04-12 Sammensetning og fremgangsmåte for behandling av hepatitt C

Country Status (23)

Country Link
US (3) US6001799A (cs)
EP (1) EP0603305B1 (cs)
JP (1) JP3228512B2 (cs)
KR (1) KR100254082B1 (cs)
AT (1) ATE152914T1 (cs)
AU (1) AU667327B2 (cs)
CA (1) CA2119006C (cs)
CZ (1) CZ286827B6 (cs)
DE (1) DE69219782T2 (cs)
DK (1) DK0603305T3 (cs)
ES (1) ES2103966T3 (cs)
FI (1) FI107879B (cs)
GR (1) GR3024025T3 (cs)
HK (1) HK1021687A1 (cs)
HU (1) HU221006B1 (cs)
MX (1) MX9205240A (cs)
NO (1) NO941310L (cs)
RO (1) RO111991B1 (cs)
RU (1) RU2104010C1 (cs)
SG (1) SG64897A1 (cs)
TW (1) TW224053B (cs)
WO (1) WO1993005806A1 (cs)
ZA (1) ZA926964B (cs)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (cs) * 1991-09-13 1994-05-21 Paul B Chretien
SG64892A1 (en) * 1992-02-06 1999-05-25 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
AU4671193A (en) * 1992-07-13 1994-01-31 Kenneth E. Sherman Composition and method of treating hepatitis b
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
TW249754B (cs) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
PT731710E (pt) * 1993-11-05 2003-09-30 Sciclone Pharmaceuticals Inc Composicoes contendo timosine alpha 1 destinadas ao tratamento de pacientes sofrendo duma doenca de figado descompensado
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
WO1997031649A1 (en) * 1996-02-28 1997-09-04 Ifi Istituto Farmacoterapico Italiano S.P.A. PHARMACEUTICAL COMPOSITIONS COMPRISING NATURAL HUMAN α-INTERFERON
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
WO2001092282A2 (en) 2000-05-26 2001-12-06 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
AU8353601A (en) * 2000-08-07 2002-02-18 Sciclone Pharmaceuticals Inc Treatment of hepatitis c with thymosin, interferon and ribavirin
WO2002044717A1 (en) * 2000-12-01 2002-06-06 Cornell Research Foundation Animal model for flaviviridae infection
RU2211703C2 (ru) * 2001-06-08 2003-09-10 ООО НТЦ "Юпитер-2" Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием
WO2003026589A2 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
CN1564693A (zh) * 2001-10-05 2005-01-12 印特缪恩股份有限公司 治疗肝纤维化和丙型肝炎病毒感染的方法
US20050054845A1 (en) * 2001-10-26 2005-03-10 Rhode Island Hospital Thymosin augmentation of genetic immunization
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
CA2476279A1 (en) * 2002-02-14 2003-08-21 Lieven J. Stuyver Modified fluorinated nucleoside analogues
AP2005003213A0 (en) 2002-06-28 2005-03-31 Univ Cagliari 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
PL374831A1 (pl) 2002-06-28 2005-10-31 Idenix (Cayman) Limited Zmodyfikowane proleki 2' i 3'-nukleozydowe do leczenia zakażeń Flaviviridae
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
JP5116972B2 (ja) 2002-12-12 2013-01-09 イデニクス(ケイマン)リミテツド 2’−分枝ヌクレオシドの製造方法
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
CN100342907C (zh) * 2003-03-28 2007-10-17 希克龙制药公司 胸腺素α1在制备用于治疗或预防哺乳动物中曲霉菌感染的药物组合物中的应用
CA2520400C (en) * 2003-03-28 2013-02-19 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
EP2345657A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
PT1658302E (pt) * 2003-07-25 2010-10-25 Centre Nat Rech Scient Análogos do nucleósido purina para o tratamento de doenças provocadas por flaviviridae incluindo hepatite c
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
KR20070011451A (ko) 2004-05-05 2007-01-24 예일 유니버시티 신규의 항바이러스 헬리오크산틴 유사체
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
AU2005285045B2 (en) 2004-09-14 2011-10-13 Gilead Sciences, Inc. Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
PL2012816T3 (pl) * 2006-05-02 2012-11-30 Sigma Tau Ind Farmaceuti Zastosowanie tymozyny 1, samej lub w kombinacji z ptx3 lub gancyklowirem, do leczenia zakażenia cytomegalowirusem
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2349315A4 (en) * 2008-10-08 2012-07-04 Univ Miami LYMPHOCYTE REGULATION AND APPLICATION
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
CN102458470B (zh) 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
SI3650014T1 (sl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (cs) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
EP0603305A1 (en) 1994-06-29
EP0603305B1 (en) 1997-05-14
US5849696A (en) 1998-12-15
CZ55194A3 (en) 1994-10-19
AU667327B2 (en) 1996-03-21
CA2119006C (en) 2005-08-23
HU9400758D0 (en) 1994-06-28
DE69219782T2 (de) 1997-10-09
AU2644792A (en) 1993-04-27
NO941310D0 (no) 1994-04-12
CZ286827B6 (cs) 2000-07-12
TW224053B (cs) 1994-05-21
DK0603305T3 (da) 1997-09-01
FI107879B (fi) 2001-10-31
WO1993005806A1 (en) 1993-04-01
HU221006B1 (hu) 2002-07-29
RO111991B1 (ro) 1997-04-30
JP3228512B2 (ja) 2001-11-12
US6001799A (en) 1999-12-14
GR3024025T3 (en) 1997-10-31
ATE152914T1 (de) 1997-05-15
HUT75166A (en) 1997-04-28
KR100254082B1 (ko) 2000-09-01
ES2103966T3 (es) 1997-10-01
US20070218033A1 (en) 2007-09-20
FI941133L (fi) 1994-03-10
FI941133A0 (fi) 1994-03-10
RU94022480A (ru) 1996-07-20
SG64897A1 (en) 1999-05-25
ZA926964B (en) 1993-04-26
JPH06510998A (ja) 1994-12-08
HK1021687A1 (en) 2000-06-23
MX9205240A (es) 1993-07-01
CA2119006A1 (en) 1993-04-01
RU2104010C1 (ru) 1998-02-10
DE69219782D1 (de) 1997-06-19

Similar Documents

Publication Publication Date Title
NO941310D0 (no) Sammensetning og fremgangsmåte for behandling av hepatitt C
DK0380230T3 (da) Immunogene sammensætninger mod gastrin-peptider
NO951340L (no) Fremgangsmåte til å behandle lungesykdom med uridintrifosfater
FR2709966B1 (fr) Vaccin pour la prévention du syndrome respiratoire et de la reproduction du porc.
DE69329558D1 (de) Verfahren zur Behandlung von Multiplesklerose
FI943028L (fi) Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi
SG46620A1 (en) Method and composition foor the treatment of autoimmune hepatitis
EP0627930A4 (en) COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
FI941705A7 (fi) Menetelmä viruspatogeenien läpipääsyn estämiseksi
ATE76579T1 (de) Interferon-zusammensetzungen.
GR3024907T3 (en) Antivenom immunesera
NO910219L (no) Behandling av tre og trebaserte materialer.
EP0452360A4 (en) Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
DE3884652D1 (de) Gate-Ausschaltthyristor und Verfahren zu dessen Herstellung.
ATE107166T1 (de) Verwendung von chlormethiazol zur herstellung eines artzneimittels zur prophylaxe oder therapie der neurodegeneration.
NO933628D0 (no) Fremgangsmaate og blanding for behandling av herpes-infeksjoner
MY110041A (en) Composition and method of treating hepatitis c
DK0497356T3 (da) Sammensætninger og fremgangsmåde til tumorer i blødt væv
NO961775L (no) Fremgangsmåte og sammensetning for behandling av pasienter med dekompensert leversykdom
ZA897105B (en) Method and composition for the treatment of viral infections
NO903504L (no) Doseringsbeholder for opptak og levering av midler for behandling av toey.
NO930550L (no) Metode og preparat for behandling av virale infeksjoner
NO910474L (no) Oppvarmet transportoer og metode for desinfisering av forurenset sykehus-avfall med liten stoerrelse.
GB9112552D0 (en) Method and composition for the treatment of cancer
SE9101471D0 (sv) Foerfarande foer tillverkning av byggelement och byggelement tillverkat enligt foerfarandet